EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TNFSF9 Is Associated with Favorable Tumor Immune Microenvironment in Patients with Renal Cell Carcinoma Who Are Treated with the Combination Therapy of Nivolumab and Ipilimumab

Bunpei Isoda iD, Shuya Kandori iD, Tomokazu Sazuka, Takahiro Kojima, Satoshi Nitta, Masanobu Shiga, Yoshiyuki Nagumo, Ayumi Fujimoto, Takayuki Arai, Hiroaki Sato iD, Bryan J Mathis iD, Chia-Ling Wu iD und 3 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25137444 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Bunpei Isoda und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Medicine, University of Tsukuba, Tsukuba 305-8577, Ibaraki, Japan. Hauptthemen laut MEDLINE: Tumor Microenvironment, Carcinoma, Renal Cell, Ipilimumab, Nivolumab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Combination therapy of nivolumab and ipilimumab (NIVO + IPI) for metastatic renal cell carcinoma (mRCC) has shown efficacy, but approximately 20% of patients experience disease progression in the early stages of treatment. No useful biomarkers have been reported to date. Therefore, it is desirable to identify biomarkers to predict treatment responses in advance. We examined the tumor microenvironment (TME)-related gene expression in mRCC patients treated with NIVO + IPI, between the response and non-response groups, using tumor tissues, before administering NIVO + IPI. In TME-related genes, TNFSF9 expression was identified as a candidate for the predictive biomarker. Its expression discriminated between the response and non-response groups with 88.89% sensitivity and 87.50% specificity (AUC = 0.9444). We further analyzed the roles of TNFSF9 in TME using bioinformatics from The Cancer Genome Atlas (TCGA) cohort. An adaptive immune response was activated in the TNFSF9-high-expression tumors. Indeed, T follicular helper cells, plasma B cells, and tumor-infiltrating CD8+ T cells were increased in the tumors, which indicates the promotion of humoral immunity due to enhanced T-B interactions. However, as the number of regulatory T cells (Treg) increased in the tumors, the percentage of dysfunctional T cells also increased. This suggests that not only PD-1 but also CTLA-4 inhibition may have suppressed Treg activation and improved the therapeutic effect in the TNFSF9 high-expression tumors. Therefore, TNFSF9 may predict the therapeutic efficacy of NIVO + IPI for mRCC and allow more appropriate patient selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentCarcinoma, Renal CellIpilimumabNivolumabKidney NeoplasmsHumansMaleFemaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsAgedBiomarkers, TumorGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

TNFSF9biomarkerimmune checkpoint inhibitor combination therapymetastatic renal cell carcinoma

Substanzen

IpilimumabNivolumabBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, Institute of Medicine, University of Tsukuba, Tsukuba 305-8577, Ibaraki, Japan.
  • Department of Urology, Graduate School of Medicine, Chiba University, Chiba 263-8522, Chiba, Japan.
  • Department of Urology, Aichi Cancer Center, Nagoya 464-8681, Aichi, Japan.
  • International Medical Center, University of Tsukuba Affiliated Hospital, Tsukuba 305-8576, Ibaraki, Japan.
  • ACT Genomics, Co., Ltd., Taipei 114, Taiwan.

ORCID-Profile: Bunpei Isoda, Shuya Kandori, Hiroaki Sato, Bryan J Mathis, Chia-Ling Wu, Tomohiko Ichikawa

Zitieren

APA

Isoda, B., Kandori, S., Sazuka, T., Kojima, T., Nitta, S., Shiga, M., Nagumo, Y., Fujimoto, A., Arai, T., Sato, H., Mathis, B. J., Wu, C. L., Jan, Y. H., Ichikawa, T., & Nishiyama, H. (2024). TNFSF9 Is Associated with Favorable Tumor Immune Microenvironment in Patients with Renal Cell Carcinoma Who Are Treated with the Combination Therapy of Nivolumab and Ipilimumab. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25137444

Vancouver

Isoda B, Kandori S, Sazuka T, Kojima T, Nitta S, Shiga M, et al. TNFSF9 Is Associated with Favorable Tumor Immune Microenvironment in Patients with Renal Cell Carcinoma Who Are Treated with the Combination Therapy of Nivolumab and Ipilimumab. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25137444

BibTeX
@article{Isoda2024,
  author = {Isoda, Bunpei and Kandori, Shuya and Sazuka, Tomokazu and Kojima, Takahiro and Nitta, Satoshi and Shiga, Masanobu and Nagumo, Yoshiyuki and Fujimoto, Ayumi and Arai, Takayuki and Sato, Hiroaki and Mathis, Bryan J and Wu, Chia-Ling and Jan, Yi-Hua and Ichikawa, Tomohiko and Nishiyama, Hiroyuki},
  title = {TNFSF9 Is Associated with Favorable Tumor Immune Microenvironment in Patients with Renal Cell Carcinoma Who Are Treated with the Combination Therapy of Nivolumab and Ipilimumab},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25137444}
}
Kostenlos starten →